Grufity logoGrufity logo

JAZZ

157.25USD+0.71(+0.45%)Market Closed

Jazz Pharmaceuticals PLC

Market Summary

USD157.25+0.71Market Closed
0.45%

JAZZ Alerts

JAZZ Stock Price

RSI Chart

Valuation

Market Cap

9.0B

Price/Earnings

-173.91

Price/Sales

2.59

Price/Cashflow

9.36

MarketCap/EBT

-105.97

Price/Sales

Profitability

EBT Margin

-2.45%

Return on Equity

-1.62%

Return on Assets

-0.46%

Fundamentals

Revenue

Revenue (TTM)

3.6B

Revenue Y/Y

12.23%

Revenue Q/Q

0.83%

Earnings

Earnings (TTM)

-18.7M

Earnings Y/Y

62.81%

Earnings Q/Q

-156.68%

Price Action

52 Week Range

119.64169.98
(Low)(High)

Last 7 days

2.8%

Last 30 days

9.8%

Last 90 days

1.5%

Trailing 12 Months

28.2%

Financial Health

Current Ratio

3.67

Debt/Equity

1.88

Debt/Cashflow

0.16

Investor Care

Shares Dilution (1Y)

2.43%

Diluted EPS (TTM)

-0.27

Peers (Alternatives to Jazz Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
459.8B
96.0B
5.64% 16.86%
24
4.79
5.02% 7.14%
342.0B
29.2B
5.87% 53.25%
60.08
11.76
5.34% 1.02%
266.2B
99.7B
9.09% -0.90%
9.08
2.63
43.92% 53.21%
255.3B
57.2B
10.70% 54.15%
15.4
4.47
35.88% 197.59%
163.4B
46.7B
4.75% 50.97%
24.47
3.5
2.79% 223.53%
MID-CAP
5.5B
4.4B
-19.59% -9.60%
-46.93
1.26
1.80% 57.67%
SMALL-CAP
1.9B
628.4M
27.93% -51.99%
-4.08
3.1
64.35% -18.14%
1.9B
659.0M
9.23% 20.30%
32.36
2.95
16.78% -53.92%
1.5B
-
32.82% -58.59%
-0.54
1.95
-4.11% -144.36%
1.2B
112.7M
16.50% -21.36%
-10.75
7.76
-54.94% 40.20%
1.1B
3.1M
16.81% -54.64%
-3.57
108.75
-77.09% -12.24%
1.0B
23.5M
9.62% 31.13%
-12.31
166.87
243.57% -1.04%
945.9M
373.2M
0.99% -19.37%
4.56
2.34
-0.39% -38.45%
283.2M
49.7M
-11.83% -51.92%
-8.71
5.67
28.95% 32.80%
68.8M
2.6B
-43.99% -88.43%
-0.03
0.02
-13.88% -4855.92%

Financials for Jazz Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue2.9%3,5843,4813,3003,0942,863
  S&GA Expenses-0.4%1,4321,4371,5001,4521,300
Earnings Before Taxes8.8%-77.62-85.12-242.20-112.8477
Net Income64.0%-18.69-51.87-449.85-329.67-160.90
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-7.3%10,38511,20011,76912,29912,478
  Current Assets-0.7%2,5722,5912,5012,6112,628
    Cash Equivalents18.0%839711491591672
  Inventory-15.5%7288629851,0731,138
  Goodwill-5.6%1,5931,6881,7821,8281,850
  Current Liabilities15.2%813705737809735
  Long Term Debt-4.9%5,7276,0216,0246,0506,278
    LT Debt, Current0%3131313131
    LT Debt, Non Current-4.9%5,6965,9905,9936,0196,247
Shareholder's Equity-14.2%2,7453,2013,6083,9653,938
  Retained Earnings-2.0%974994959830866
  Additional Paid-In Capital2.3%3,3883,3123,2393,5353,470
Shares Outstanding0.9%62626261-
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations14.9%1,108964702779787
  Share Based Compensation1.6%214210205189167
Cashflow From Investing19.2%-131.94-163.36-5,986.57-5,212.14-5,128.83
Cashflow From Financing18.1%-795.70-971.823,6813,9714,273
  Buy Backs0%0000
* denotes actual numbers (not divided by Millions)

Risks

What is the probability of a big loss on JAZZ?

63.9%


Probability that Jazz Pharmaceuticals stock will be more than 20% underwater in next one year

49.6%


Probability that Jazz Pharmaceuticals stock will be more than 30% underwater in next one year.

0%


Probability that Jazz Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does JAZZ drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Jazz Pharmaceuticals was unfortunately bought at previous high price.

Returns

Cumulative Returns on JAZZ

11.8%


10-Year Cumulative Returns

1.2%


7-Year Cumulative Returns

2.6%


5-Year Cumulative Returns

2.4%


3-Year Cumulative Returns

What are the long-term rolling returns for JAZZ?

FIve years rolling returns for Jazz Pharmaceuticals.

Which funds bought or sold JAZZ recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Toroso Investments, LLC
NEW
-
262,000
262,000
0.01%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
20,723,000
20,723,000
0.24%
2022-11-21
DEARBORN PARTNERS LLC
SOLD OFF
-100
-211,000
-
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
ADDED
0.55
-2,328,000
14,188,000
0.02%
2022-11-21
FourThought Financial, LLC
REDUCED
-7.04
-2,000
9,000
-%
2022-11-18
Power Corp of Canada
UNCHANGED
-
-262,000
1,538,000
0.23%
2022-11-17
CENTRAL TRUST Co
REDUCED
-9.19
-578,000
2,004,000
0.07%
2022-11-17
M&T Bank Corp
REDUCED
-10.18
520,000
1,026,000
-%
2022-11-16
Front Row Advisors LLC
NEW
-
6,000
6,000
-%
2022-11-16
Neo Ivy Capital Management
NEW
-
216,000
216,000
0.57%

1–10 of 44

Latest Funds Activity

Are funds buying JAZZ calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own JAZZ

Jazz Pharmaceuticals News

InvestorsObserver

Is Jazz Pharmaceuticals PLC (JAZZ) Stock at the Top of the Biotechnology Industry?.29 hours ago

JAZZ Fair Value

Recent SEC filings of Jazz Pharmaceuticals

View All Filings
Date Filed Form Type Document
Nov 18, 2022
4
Insider Trading
Nov 16, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
4
Insider Trading
Nov 14, 2022
8-K
Current Report
Nov 09, 2022
10-Q
Quarterly Report
Nov 09, 2022
8-K
Current Report
Oct 19, 2022
8-K
Current Report
Oct 05, 2022
4
Insider Trading
Sep 09, 2022
4
Insider Trading

Latest Insider Trading transactions for JAZZ

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-16
Patil Neena M
SOLD
-499,613
142.34
-3,510
EVP & Chief Legal Officer
2022-11-14
Larkin Finbar
SOLD
-29,418
149.33
-197
SVP, Technical Operations
2022-11-10
COZADD BRUCE C
SOLD
-300,000
150
-2,000
Chairman & CEO
2022-11-10
Pearce Samantha
SOLD
-164,765
155
-1,063
SVP, Head of Europe & Internat
2022-11-10
Pearce Samantha
ACQUIRED
116,345
109.45
1,063
SVP, Head of Europe & Internat
2022-09-07
Larkin Finbar
SOLD
-9,450
150
-63
SVP, Technical Operations
2022-09-06
COZADD BRUCE C
SOLD
-1,179,970
153.183
-7,703
Chairman & CEO
2022-09-06
COZADD BRUCE C
ACQUIRED
573,561
59.13
9,700
Chairman & CEO
2022-09-02
Pearce Samantha
ACQUIRED
58,117.9
109.45
531
SVP, Head of Europe & Internat
2022-09-02
Pearce Samantha
SOLD
-83,356.4
156.98
-531
SVP, Head of Europe & Internat

1–10 of 50

Bruce C. Cozadd
3200
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

JAZZ Income Statement

2022-09-30
Condensed Consolidated Statements of Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total revenues$ 940,652$ 838,115$ 2,687,251$ 2,197,507
Operating expenses:    
Cost of product sales (excluding amortization of acquired developed technologies)133,661145,224373,153304,607
Selling, general and administrative358,478363,6821,033,7641,053,221
Research and development148,870141,036417,898350,305
Intangible asset amortization141,232159,804461,782368,476
Acquired in-process research and development0069,1480
Impairment charge133,6480133,6480
Total operating expenses915,889809,7462,489,3932,076,609
Income from operations24,76328,369197,858120,898
Interest expense, net(80,244)(93,372)(214,117)(190,168)
Foreign exchange gain (loss)(4,649)(2,631)(16,532)1,262
Loss before income tax expense (benefit) and equity in loss (gain) of investees(60,130)(67,634)(32,791)(68,008)
Income tax expense (benefit)(43,027)(18,057)(58,603)228,583
Equity in loss (gain) of investees2,5453,2569,148(2,274)
Net income (loss)$ (19,648)$ (52,833)$ 16,664$ (294,317)
Net income (loss) per ordinary share:    
Basic (in dollars per share)$ (0.31)$ (0.86)$ 0.27$ (4.98)
Diluted (in dollars per share)$ (0.31)$ (0.86)$ 0.26$ (4.98)
Weighted-average ordinary shares used in per share calculations - basic (in shares)62,78561,28462,36559,084
Weighted-average ordinary shares used in per share calculations - diluted (in shares)62,78561,28463,38859,084
Product sales, net    
Revenues:    
Total revenues$ 935,766$ 834,247$ 2,673,903$ 2,186,118
Royalties and contract revenues    
Revenues:    
Total revenues$ 4,886$ 3,868$ 13,348$ 11,389

JAZZ Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 839,358$ 591,448
Investments60,0000
Accounts receivable, net of allowances601,179563,360
Inventories728,0741,072,721
Prepaid expenses92,877131,413
Other current assets250,016252,392
Total current assets2,571,5042,611,334
Property, plant and equipment, net216,339256,837
Operating lease assets73,72886,586
Intangible assets, net5,570,3947,152,328
Goodwill1,592,6351,827,609
Deferred tax assets, net314,965311,103
Deferred financing costs9,94912,029
Other non-current assets35,15340,813
Total assets10,384,66712,298,639
Current liabilities:  
Accounts payable102,249100,298
Accrued liabilities668,390666,304
Current portion of long-term debt31,00031,000
Income taxes payable10,4449,608
Deferred revenue8712,093
Total current liabilities812,954809,303
Deferred revenue, non-current116463
Long-term debt, less current portion5,695,8146,018,943
Operating lease liabilities, less current portion72,98487,200
Deferred tax liabilities, net933,6701,300,541
Other non-current liabilities123,935116,998
Commitments and contingencies (Note 10)
Shareholders’ equity:  
Ordinary shares66
Non-voting euro deferred shares5555
Capital redemption reserve472472
Additional paid-in capital3,387,9973,534,792
Accumulated other comprehensive loss(1,617,646)(400,360)
Retained earnings974,310830,226
Total shareholders’ equity2,745,1943,965,191
Total liabilities and shareholders’ equity$ 10,384,667$ 12,298,639